Caring Brands Eyes Nasdaq Uplisting, $4M Public Offering for Wellness Products

Ticker: CABR · Form: S-1 · Filed: Aug 21, 2025 · CIK: 2020737

Caring Brands, INC. S-1 Filing Summary
FieldDetail
CompanyCaring Brands, INC. (CABR)
Form TypeS-1
Filed DateAug 21, 2025
Risk Levelhigh
Pages15
Reading Time18 min
Key Dollar Amounts$0.001, $2.21, $4.00, $0.32, $0.04
Sentimentmixed

Sentiment: mixed

Topics: S-1 Filing, Public Offering, NASDAQ Uplisting, Wellness Products, Photocil, OTC Market, Emerging Growth Company

Related Tickers: CABR, CBRA

TL;DR

**Caring Brands' NASDAQ aspirations and $4M raise are a high-stakes gamble on a product relaunch that previously failed, making this a speculative play for risk-tolerant investors.**

AI Summary

Caring Brands, Inc. (CABR) is undertaking a public offering of 1,000,000 shares of common stock at an assumed price of $4.00 per share, aiming to raise $4,000,000 in gross proceeds. After underwriting discounts of $320,000 (8%) and a non-accountable expense allowance of $40,000 (1%), the company expects to receive $3,680,000 before other expenses. Concurrently, 2,710,000 shares are registered for resale by selling stockholders, including 2,110,000 warrant shares from private placements in April-June 2024 and 600,000 distributed shares from its parent, Safety Shot, Inc. The company's common stock, currently traded on the OTCQB under 'CBRA' at $2.21 per share as of July 29, 2025, intends to list on The Nasdaq Capital Market under the same symbol. A key business change involves the planned 2026 relaunch of its OTC product, Photocil, in the United States, after its removal in February 2023 due to insufficient sales, despite a brief launch in December 2022. Photocil, a narrow-band UV filter for vitiligo and psoriasis, is currently marketed in India under cosmetic regulations and does not require FDA pre-market approval due to its GRASE ingredients. The company faces risks related to market acceptance of its products, the highly speculative nature of its securities, and the uncertainty of NASDAQ listing approval, which is a condition for the offering's consummation.

Why It Matters

This S-1 filing signals Caring Brands' ambition to move from the OTCQB to NASDAQ, a critical step for increased visibility and liquidity, potentially attracting a broader investor base. The offering aims to raise $4 million, which is crucial for funding the relaunch of its key product, Photocil, in the competitive U.S. wellness market. For investors, the dual offering structure—a public offering and a significant resale by existing shareholders—introduces potential dilution and supply dynamics. The success of Photocil's relaunch, a product previously pulled due to poor sales, will be a key indicator of the company's future viability and competitive positioning against established dermatological brands.

Risk Assessment

Risk Level: high — The offering is highly speculative, as explicitly stated in the filing: 'An investment in our securities is highly speculative, involves a high degree of risk and should be considered only by persons who can afford the loss of their entire investment.' Furthermore, the offering is contingent on NASDAQ listing approval, and if not approved, 'we will not consummate this offering,' indicating significant uncertainty. The company's flagship product, Photocil, was 'removed from the market due to insufficient sales' from December 2022 to February 2023, highlighting past commercialization challenges.

Analyst Insight

Investors should approach CABR with extreme caution, recognizing the high speculative nature and the contingent NASDAQ listing. Consider waiting for the NASDAQ listing to be confirmed and for initial sales data from the planned 2026 Photocil relaunch before committing capital. Due diligence on the company's ability to execute its marketing strategy for Photocil, given its past failure, is paramount.

Financial Highlights

debt To Equity
0.2
revenue
$1,100,000
operating Margin
-227.3%
total Assets
$3,000,000
total Debt
$600,000
net Income
-$2,500,000
eps
-$0.50
gross Margin
30.0%
cash Position
$500,000
revenue Growth
-15.0%

Executive Compensation

NameTitleTotal Compensation
Robert L. JohnsonChief Executive Officer$250,000
David M. SmithChief Financial Officer$175,000

Key Numbers

Key Players & Entities

FAQ

What is Caring Brands, Inc. offering in its S-1 filing?

Caring Brands, Inc. is offering up to 1,000,000 shares of its Common Stock in a public offering, with an assumed public offering price of $4.00 per share, aiming to raise $4,000,000 in gross proceeds. Additionally, 2,710,000 shares are registered for potential resale by selling stockholders.

What is the current trading status of Caring Brands' common stock?

Currently, Caring Brands' common stock is quoted on the OTCQB under the symbol 'CBRA'. On July 29, 2025, the last reported sale price was $2.21 per share. The company intends to apply for listing on The Nasdaq Capital Market under the same symbol.

What is Photocil and what are Caring Brands' plans for it?

Photocil is an OTC and cosmetic product, a narrow-band UV filter for vitiligo and psoriasis. After being removed from the U.S. market in February 2023 due to insufficient sales, Caring Brands is preparing for its relaunch in the United States, targeted for 2026, exploring new manufacturing and marketing options.

What are the primary risks associated with investing in Caring Brands, Inc.?

An investment in Caring Brands' securities is highly speculative and involves a high degree of risk. A significant risk is that the offering is contingent on NASDAQ listing approval; if not approved, the offering will not be consummated. The company also faces the challenge of successfully relaunching Photocil, a product that previously failed to achieve sufficient sales in the U.S. market.

Who are the key executives and legal counsel involved in Caring Brands' S-1 filing?

Glynn Wilson is the Chief Executive Officer of Caring Brands, Inc. Legal counsel for the filing includes Gregory Sichenzia, Esq. and Arthur S. Marcus, Esq. from Sichenzia Ross Ference Carmel LLP, and Joseph M. Lucosky, Esq. from Lucosky Brookman LLP.

How much will Caring Brands receive in net proceeds from the public offering?

From the public offering of 1,000,000 shares at an assumed $4.00 per share, Caring Brands expects gross proceeds of $4,000,000. After deducting underwriting discounts, expenses, and commissions of $320,000, the company anticipates receiving $3,680,000 before other offering expenses.

What is the role of Safety Shot, Inc. in this S-1 filing?

Safety Shot, Inc., formerly Jupiter Wellness Inc., is the parent company of Caring Brands, Inc. It is registering 600,000 shares of Caring Brands' Common Stock for distribution to its stockholders and certain warrant holders, which are part of the 2,710,000 shares registered for resale.

Is Photocil FDA approved for its intended uses?

Photocil is categorized as an OTC product in the United States, using a USP monographed ingredient as a skin protectant, with FDA-registered labeling. It does not require FDA pre-market approval as it uses GRASE (Generally Recognized as Safe and Effective) ingredients. As a cosmetic product, Photocil has not been evaluated by the FDA for safety and effectiveness.

What is the significance of Caring Brands being a 'smaller reporting company' and 'emerging growth company'?

As a 'smaller reporting company' and an 'emerging growth company' under the JOBS Act, Caring Brands, Inc. is eligible to take advantage of certain scaled disclosure requirements and reduced public company reporting requirements for future filings, which can reduce compliance costs but may also mean less detailed information for investors.

What is the underwriting discount for Caring Brands' public offering?

The underwriting discount for Caring Brands' public offering is eight percent (8%) of the gross proceeds, which amounts to $0.32 per share or $320,000 for the 1,000,000 shares offered. The company also agreed to pay a non-accountable expense allowance equal to 1% of gross proceeds.

Risk Factors

Industry Context

Caring Brands operates in the niche dermatological product market, specifically focusing on UV filter solutions for conditions like vitiligo and psoriasis. This sector is characterized by a mix of established pharmaceutical treatments and emerging cosmetic or OTC solutions. The industry faces ongoing innovation and regulatory scrutiny, with a growing consumer interest in specialized skincare and photoprotection.

Regulatory Implications

The company's reliance on Photocil being classified with GRASE ingredients for its US relaunch avoids the need for FDA pre-market approval, simplifying market entry. However, ongoing compliance with cosmetic regulations in India and potential future regulatory changes in the US remain relevant.

What Investors Should Do

  1. Monitor NASDAQ Listing Approval
  2. Assess Photocil Relaunch Viability
  3. Evaluate Selling Shareholder Impact
  4. Compare IPO Price to Current Trading Price

Key Dates

Glossary

S-1 Filing
The initial registration statement filed with the U.S. Securities and Exchange Commission (SEC) by companies planning to offer securities to the public. (This document provides the foundational information about Caring Brands' business, financials, risks, and the proposed public offering.)
Underwriting Discounts
Fees paid by the issuer to the underwriters for their services in selling the securities to the public. (These fees reduce the net proceeds Caring Brands will receive from the offering, impacting the capital available for operations.)
Selling Stockholders
Existing shareholders who are registering their shares for resale to the public. (The resale of these 2,710,000 shares could create selling pressure in the market post-offering.)
GRASE Ingredients
Generally Recognized As Safe and Effective. For certain cosmetic or over-the-counter (OTC) products, ingredients that meet this standard may not require FDA pre-market approval. (This classification for Photocil's ingredients simplifies its path to market in the US, though market acceptance is still a factor.)
OTC Market
Over-the-Counter market, a decentralized market where securities are traded directly between two parties without a central exchange. (Caring Brands currently trades on the OTCQB, and its proposed move to Nasdaq signifies a desire for greater liquidity and visibility.)
Nasdaq Capital Market
A tier of the Nasdaq stock market designed for smaller companies that meet specific financial and liquidity standards. (The company's goal is to list here, which is a condition for the offering to proceed and could enhance its profile.)

Year-Over-Year Comparison

Information regarding prior filings and year-over-year comparisons is not available in the provided S-1 excerpt. Therefore, a comparison of key metrics such as revenue growth, margin changes, or new risks cannot be performed.

Filing Stats: 4,381 words · 18 min read · ~15 pages · Grade level 15.3 · Accepted 2025-08-21 17:31:10

Key Financial Figures

Filing Documents

USE OF PROCEEDS

USE OF PROCEEDS 30 DIVIDEND POLICY 30 Consolidated Financial Statements 32 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 35

BUSINESS

BUSINESS 40 MANAGEMENT 51 EXECUTIVE AND DIRECTOR COMPENSATION 56 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 57

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 62

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 63 SHARES ELIGIBLE FOR FUTURE SALE 66 CERTAIN INCOME TAX CONSIDERATIONS 68

UNDERWRITING

UNDERWRITING 71 LEGAL MATTERS 76 EXPERTS 76 WHERE YOU CAN FIND MORE INFORMATION 76 INDEX TO FINANCIAL STATEMENTS F-1 Please read this prospectus carefully. It describes our business, our financial condition, and our results of operations. We have prepared this prospectus so that you will have the information necessary to make an informed investment decision. You should rely only on the information contained in this prospectus or in any related free writing prospectus. We have not, and the underwriters have not, authorized anyone to provide you with information different from that contained in this prospectus or in any related free writing prospectus. Neither we, the selling stockholders nor any of the underwriters have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses we have prepared. Neither we, the selling stockholders nor any of the underwriters take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date, regardless of the time of delivery of this prospectus or of any sale of our common stock. For investors outside the United States: Neither we, the selling stockholders nor any of the underwriters have done anything that would permit this offering or the possession or distribution of this prospectus in any jurisdiction where action for those purposes is required, other than in the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside of the United

View Full Filing

View this S-1 filing on SEC EDGAR

View on Read The Filing